(Press-News.org) A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are a significant invasive disease-free survival benefit in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
Researchers found that patients who took the combination therapy had substantially longer invasive disease-free survival compared to those who were treated with the hormone therapy alone, regardless of whether the cancer has spread to the lymph nodes. The addition of the targeted therapy reduced the risk of recurrence by 25%.
The results were shared today during the American Society of Clinical Oncology Annual Meeting by Dr. Dennis Slamon, chair of hematology-oncology and director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center.
“The results from the clinical trial have immediate implications for patients,” said Slamon. “The findings show this combination is a treatment of choice for patients with stage 2 or stage 3 HR positive/HER2 negative breast cancer.”
HR positive/HER2 negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States.
Previously, Slamon and researchers at the Jonsson Cancer Center demonstrated that adding ribociclib, a cyclin-dependent kinase inhibitor, to the standard hormone therapy improves overall survival in both premenopausal and postmenopausal women with metastatic HR positive/HER2 negative breast cancer.
Slamon also led the discovery program that found that cyclin-dependent kinase inhibitors are effective in treating hormone receptor positive breast cancer. These drugs work by blocking the activity of cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.
This work ultimately helped lead to the FDA approval of ribociclib and other related drugs to treat metastatic breast cancer. There are now three CDK4/6 inhibitors that have been approved by the FDA for combination treatment with standard hormone therapies in the metastatic setting.
Building on this past research, the team assessed whether the treatment combination could also improve outcomes in early breast cancer.
The clinical trial, called NATALEE, involved 5101 patients with stage 2 or stage 3 early HR positive/HER2 negative breast cancer. Patients were randomized into two arms: 2549 were randomized to the combination treatment and 2552 to the hormone therapy alone. Invasive disease-free survival was the primary endpoint of the study.
The median duration on study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20% and 57% patients respectively. Invasive disease-free survival was evaluated after 426 events.
At the time of this analysis, 189 people in the ribociclib group (7.4% of patients) experienced an invasive disease-free survival event, compared to 237 people in the hormone therapy alone group (9.3% of patients). The data showed a statistically significant improvement in the risk of invasive disease in favor of the combination arm.
The invasive disease-free survival rates at three years were 90.4%, compared to 87.1% for women who were treated with only hormone therapy.
Ribociclib at 400 mg had a favorable safety profile with no new signals.
“Overall, the combination therapy showed more favorable outcomes, significantly reducing the risk of the cancer returning,” Slamon said. “These results should change how we evaluate and treat patients.”
The study was sponsored by Novartis, which developed ribociclib at the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.
END
ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer
The addition of ribociclib reduced the risk of the cancer returning by 25%
2023-06-02
ELSE PRESS RELEASES FROM THIS DATE:
New research suggests wheat crops may be threatened by unprecedented heat and drought
2023-06-02
The world is getting hotter, causing shifts in seasonal patterns and increasing the amount of extreme weather such as severe droughts and heat waves, which can affect crop yields and food supplies. A recent study led by a researcher at the Friedman School of Nutrition Science and Policy at Tufts University found that the likelihood of extreme temperatures that could affect crop yields has increased significantly in wheat-producing regions of the U.S. and China.
The findings predict heat waves that happened approximately ...
Eventually everything will evaporate, not only black holes
2023-06-02
New theoretical research by Michael Wondrak, Walter van Suijlekom and Heino Falcke of Radboud University has shown that Stephen Hawking was right about black holes, although not completely. Due to Hawking radiation, black holes will eventually evaporate, but the event horizon is not as crucial as had been believed. Gravity and the curvature of spacetime cause this radiation too. This means that all large objects in the universe, like the remnants of stars, will eventually evaporate.
Using a clever combination of quantum physics and Einstein’s theory of gravity, Stephen Hawking argued that the spontaneous creation and annihilation ...
Underwater forest's recovery offers hope for marine restoration across the globe
2023-06-02
Human activity has degraded ecosystems and damaged biodiversity around the world, but ecosystem restoration offers hope for the future. Scientists studying the restoration of underwater seaweed forests which provide other species with food and shelter have found that 10 years of restoration efforts have helped a damaged forest regrow to richness and strength comparable to forests that have never been disturbed.
“Macroalgal forests are found along over one-third of the world’s coastlines and underpin ...
Developing technologies to reduce the cost of green hydrogen production
2023-06-02
Green hydrogen, which produces hydrogen without the use of fossil fuels or the emission of carbon dioxide, has become increasingly important in recent years as part of efforts to realize a decarbonized economy. However, due to the high production cost of water electrolysis devices that produce green hydrogen, the economic feasibility of green hydrogen has not been very high. However, the development of a technology that drastically reduces the amount of rare metals such as iridium and platinum used in polymer electrolyte membrane water electrolysis devices is opening the way to lower production costs.
A research team led by Dr. Hyun S. Park and Sung Jong ...
ASCO 2023 - Sylvester Comprehensive Cancer Center experts available for interviews
2023-06-02
Sarcomas
Dr. Jonathan C. Trent, a medical oncologist specializing in Sarcoma and Connective Tissue Medical Oncology at Sylvester, is available to discuss a wide range of issues related to Sarcoma research and experimental therapeutics. He and collaborators are involved in multiple ASCO23 presentations, including:
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have ...
Alcohol dependency in adolescence, but not consumption, linked with later depression risk
2023-06-02
Adolescents who show signs of alcohol dependence are more likely to develop depression by their mid-20s, according to a new study led by UCL (University College London) and University of Bristol researchers.
Drinking large amounts of alcohol regularly, but with no signs of dependency, did not predict depression risk, according to the findings published in The Lancet Psychiatry.
Co-lead author Dr Gemma Lewis (UCL Psychiatry) said: “By using a large, longitudinal dataset, we have found evidence that problematic drinking patterns in late adolescence may increase the risk of developing ...
Why we need to fall out of love with flaky white fish - study
2023-06-02
The UK’s growing mismatch between the fish we catch and the fish we want to eat has clear implications for our future food security, according to new research.
Led by the University of Essex and the Centre for Environment Fisheries and Aquaculture Science (Cefas), the study, published in the international peer-reviewed journal Reviews in Fish Biology and Fisheries, for the first time offers a comprehensive, long-term analysis of how major policy changes in the past 120 years have influenced patterns in UK seafood production, trade and consumption.
It shows that even if we changed our fish-eating habits away from choosing flaky white fish such as cod ...
UK’s poorest children likelier to have less understanding of personal finances, study finds
2023-06-02
A new study of 3,745 families from across the UK demonstrates a “sizeable” gap in the financial knowledge of children depending on which socio-economic group they come from.
The research highlights significant inequalities in young people’s financial capabilities, with the results pointing toward disadvantaged children not developing key financial skills.
In findings published in the peer-reviewed British Journal of Educational Studies, an expert team from UCL are calling for a greater emphasis on developing financial skills amongst children starting at primary school, particularly aimed towards those from disadvantaged social backgrounds, with “a particular need ...
ASCO 23: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are changing the surgeon’s role
2023-06-02
DOWNLOADABLE B-ROLL/VIDEO
MIAMI, FLORIDA (June 1, 2023) – Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as targeted therapies and other new medications emerge, surgery for certain patients may become more of a secondary option if those treatments fail. This new context could potentially change how some procedures are conducted.
Otolaryngologist and head and neck surgeon Dr. Zoukaa Sargi, will join a June 2 panel discussion on thyroid cancer care ...
Medical College of Wisconsin cancer researcher & key investigator on study of Pirtobrutinib, now FDA approved for patients previously treated for Mantle Cell Lymphoma
2023-06-02
In a multicenter phase 1 and 2 trial (BRUIN, NCT03740529), researchers from leading cancer centers across the globe, including the Medical College of Wisconsin (MCW) in Milwaukee, tested Bruton tyrosine kinase inhibitor (BTKi), pirtobrutinib, in patients with pre-treated mantle cell lymphoma (MCL). Results of the study, which assessed the efficacy of the drug in a cohort of 90 patients with poor survival prognosis, demonstrated the reversible BTKi drug to be both safe and effective in achieving inhibition of defective B-cells. The results were published by the Journal of Clinical Oncology on May 16.
MCL is an aggressive, rare subtype of ...
LAST 30 PRESS RELEASES:
Hoarding disorder: ‘sensory CBT’ treatment strategy shows promise
Water fluoridation less effective now than in past
Toddlers get nearly half their calories from ultra-processed foods
Detroit researchers to examine links between bacterial infections, environmental pollution and preterm birth
In lab tests, dietary zinc inhibits AMR gene transmission
Two UMD Astronomy space probes advance to next round of $1 billion NASA mission selection
New MSU research sheds light on impact and bias of voter purging in Michigan
Funding to create world's first ovarian cancer prevention vaccine
Scientists develop novel method for strengthening PVC products
Houston Methodist part of national consortium to develop vaccine against herpesviruses
UT Health San Antonio School of Dentistry earns first NIH grant under new center for pain therapeutics and addiction research
Do MPH programs prepare graduates for employment in today's market? Mostly yes, but who is hiring may be surprising
New article provides orientation to using implementation science in policing
Three beer-related discoveries to celebrate Oktoberfest
AAAS launches user research project to inform the new AAAS.org
In odd galaxy, NASA's Webb finds potential missing link to first stars
Adding beans and pulses can lead to improved shortfall nutrient intakes and a higher diet quality in American adults
What happens in the brain when a person with schizophrenia “hears voices”?
Ant agriculture began 66 million years ago in the aftermath of the asteroid that doomed the dinosaurs
A new era of solar observation
The true global impact of species-loss caused by humans is far greater than expected – new study reveals
Smartphone-assisted “scavenger hunt” identifies people at risk for dementia
Green subsidies may have hidden costs, experts warn
Small brains can accomplish big things, according to new theoretical research
UTA professor honored for science education leadership
Decline of mpox antibody responses after modified vaccinia Ankara–Bavarian Nordic vaccination
Wider use of convalescent plasma might have saved thousands more lives during pandemic
Strong coupling between Andreev qubits mediated by a microwave resonator
UNF biological sciences professor receives NIH grant to study muscle atrophy
Child Health Day 2024: influenza vaccine protects children from infection and hospitalization for the disease, Spanish study shows
[Press-News.org] ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancerThe addition of ribociclib reduced the risk of the cancer returning by 25%